APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulomatosis with Polyangiitis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Granulomatosis with Polyangiitis Drug Industry Growth and Trends Forecast to 2032

26 December 2025104 pages

Choose your research edition.

Industry ResearchGranulomatosis with Polyangiitis Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulomatosis with Polyangiitis Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Granulomatosis with Polyangiitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulomatosis with Polyangiitis Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulomatosis with Polyangiitis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulomatosis with Polyangiitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulomatosis with Polyangiitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulomatosis with Polyangiitis Drug include Sandoz International GmbH, GlaxoSmithKline Plc, The International Biotechnology Center (IBC) Generium, Panacea Biotec Ltd, Iltoo Pharma, Genor BioPharma Co Ltd, Coherus BioSciences Inc, ChemoCentryx Inc and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Granulomatosis with Polyangiitis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Granulomatosis with Polyangiitis Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Granulomatosis with Polyangiitis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Granulomatosis with Polyangiitis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Granulomatosis with Polyangiitis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Granulomatosis with Polyangiitis Drug Market by Company

Sandoz International GmbH

GlaxoSmithKline Plc

The International Biotechnology Center (IBC) Generium

Panacea Biotec Ltd

Iltoo Pharma

Genor BioPharma Co Ltd

Coherus BioSciences Inc

ChemoCentryx Inc

Bristol-Myers Squibb Company

Bionovis SA

Granulomatosis with Polyangiitis Drug Segment by Type

Avacopan

Benralizumab

Rituximab Biosimilar

Others

Granulomatosis with Polyangiitis Drug Segment by Application

Hospital

Clinic

Others

Granulomatosis with Polyangiitis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulomatosis with Polyangiitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulomatosis with Polyangiitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulomatosis with Polyangiitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Granulomatosis with Polyangiitis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Granulomatosis with Polyangiitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Avacopan Table 2. Major Company of Benralizumab Table 3. Major Company of Rituximab Biosimilar Table 4. Major Company of Others Table 5. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 7. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2021-2026) Table 8. Global Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 9. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type (2021-2026) Table 10. Global Granulomatosis with Polyangiitis Drug Price by Type (2021-2026) & (US$/Unit) Table 11. Global Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (W Units) Table 12. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2027-2032) Table 13. Global Granulomatosis with Polyangiitis Drug Sales by Type (2027-2032) & (US$ Million) Table 14. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type (2027-2032) Table 15. Global Granulomatosis with Polyangiitis Drug Price by Type (2027-2032) & (US$/Unit) Table 16. North America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 17. North America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 19. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 21. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 23. Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (W Units) Table 25. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Granulomatosis with Polyangiitis Drug Industry Trends Table 27. Granulomatosis with Polyangiitis Drug Industry Drivers Table 28. Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges Table 29. Granulomatosis with Polyangiitis Drug Industry Restraints Table 30. Global Granulomatosis with Polyangiitis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Company (2021-2026) Table 32. Global Granulomatosis with Polyangiitis Drug Sales by Company (2021-2026) & (W Units) Table 33. Global Granulomatosis with Polyangiitis Drug Sales Share by Company (2021-2026) Table 34. Global Granulomatosis with Polyangiitis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Granulomatosis with Polyangiitis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Granulomatosis with Polyangiitis Drug Major Company Production Sites and Headquarters Table 37. Global Granulomatosis with Polyangiitis Drug Company, Product Type & Application Table 38. Global Granulomatosis with Polyangiitis Drug Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Granulomatosis with Polyangiitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Granulomatosis with Polyangiitis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026) & (W Units) Table 43. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2021-2026) Table 44. Global Granulomatosis with Polyangiitis Drug Sales by Region (2021-2026) & (US$ Million) Table 45. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2021-2026) Table 46. Global Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2027-2032) Table 49. Global Granulomatosis with Polyangiitis Drug Sales by Region (2027-2032) & (US$ Million) Table 50. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2027-2032) Table 51. Global Granulomatosis with Polyangiitis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 54. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2021-2026) Table 55. Global Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 56. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2021-2026) Table 57. Global Granulomatosis with Polyangiitis Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (W Units) Table 59. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2027-2032) Table 60. Global Granulomatosis with Polyangiitis Drug Sales by Application (2027-2032) & (US$ Million) Table 61. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2027-2032) Table 62. Global Granulomatosis with Polyangiitis Drug Price by Application (2027-2032) & (US$/Unit) Table 63. North America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 64. North America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 66. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 68. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 70. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (W Units) Table 72. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Sandoz International GmbH Company Information Table 74. Sandoz International GmbH Business Overview Table 75. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio Table 77. Sandoz International GmbH Recent Development Table 78. GlaxoSmithKline Plc Company Information Table 79. GlaxoSmithKline Plc Business Overview Table 80. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio Table 82. GlaxoSmithKline Plc Recent Development Table 83. The International Biotechnology Center (IBC) Generium Company Information Table 84. The International Biotechnology Center (IBC) Generium Business Overview Table 85. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio Table 87. The International Biotechnology Center (IBC) Generium Recent Development Table 88. Panacea Biotec Ltd Company Information Table 89. Panacea Biotec Ltd Business Overview Table 90. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 92. Panacea Biotec Ltd Recent Development Table 93. Iltoo Pharma Company Information Table 94. Iltoo Pharma Business Overview Table 95. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio Table 97. Iltoo Pharma Recent Development Table 98. Genor BioPharma Co Ltd Company Information Table 99. Genor BioPharma Co Ltd Business Overview Table 100. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio Table 102. Genor BioPharma Co Ltd Recent Development Table 103. Coherus BioSciences Inc Company Information Table 104. Coherus BioSciences Inc Business Overview Table 105. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 107. Coherus BioSciences Inc Recent Development Table 108. ChemoCentryx Inc Company Information Table 109. ChemoCentryx Inc Business Overview Table 110. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio Table 112. ChemoCentryx Inc Recent Development Table 113. Bristol-Myers Squibb Company Company Information Table 114. Bristol-Myers Squibb Company Business Overview Table 115. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio Table 117. Bristol-Myers Squibb Company Recent Development Table 118. Bionovis SA Company Information Table 119. Bionovis SA Business Overview Table 120. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio Table 122. Bionovis SA Recent Development Table 123. North America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 124. North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 125. North America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 126. North America Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 127. North America Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Country (2027-2032) Table 128. North America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. North America Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. North America Granulomatosis with Polyangiitis Drug Market Share by Country (2021-2026) Table 131. North America Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. North America Granulomatosis with Polyangiitis Drug Market Share Forecast by Country (2027-2032) Table 133. Europe Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 134. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 135. Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 136. Europe Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 137. Europe Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Country (2027-2032) Table 138. Europe Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Granulomatosis with Polyangiitis Drug Market Share by Country (2021-2026) Table 141. Europe Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Granulomatosis with Polyangiitis Drug Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 145. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 146. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 147. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Share by Country (2021-2026) Table 151. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Share Forecast by Country (2027-2032) Table 153. Latin America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 154. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 155. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 156. Latin America Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 157. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Country (2027-2032) Table 158. Latin America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Granulomatosis with Polyangiitis Drug Market Share by Country (2021-2026) Table 161. Latin America Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Granulomatosis with Polyangiitis Drug Market Share Forecast by Country (2027-2032) Table 163. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 164. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026) & (W Units) Table 165. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Country (2021-2026) Table 166. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 167. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Country (2027-2032) Table 168. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Share by Country (2021-2026) Table 171. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Share Forecast by Country (2027-2032) Table 173. Key Raw Materials Table 174. Raw Materials Key Suppliers Table 175. Granulomatosis with Polyangiitis Drug Distributors List Table 176. Granulomatosis with Polyangiitis Drug Customers List Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Granulomatosis with Polyangiitis Drug Image Figure 2. Global Granulomatosis with Polyangiitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulomatosis with Polyangiitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulomatosis with Polyangiitis Drug Sales (2021-2032) & (W Units) Figure 5. Avacopan Image Figure 6. Global Avacopan Sales YoY Growth (2021-2032) & (W Units) Figure 7. Benralizumab Image Figure 8. Global Benralizumab Sales YoY Growth (2021-2032) & (W Units) Figure 9. Rituximab Biosimilar Image Figure 10. Global Rituximab Biosimilar Sales YoY Growth (2021-2032) & (W Units) Figure 11. Others Image Figure 12. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 13. Global Granulomatosis with Polyangiitis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Granulomatosis with Polyangiitis Drug Market Share by Type 2025 VS 2032 Figure 15. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2025 Figure 16. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2025 Figure 17. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2025 Figure 18. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2025 Figure 21. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Granulomatosis with Polyangiitis Drug Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Image Figure 28. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 29. Clinic Image Figure 30. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 33. Global Granulomatosis with Polyangiitis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Granulomatosis with Polyangiitis Drug Market Share by Application 2025 VS 2032 Figure 35. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2025 Figure 36. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2025 Figure 37. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2025 Figure 38. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2025 Figure 41. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2025 Figure 45. North America Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. North America Granulomatosis with Polyangiitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Granulomatosis with Polyangiitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Europe Granulomatosis with Polyangiitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Granulomatosis with Polyangiitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Granulomatosis with Polyangiitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Latin America Granulomatosis with Polyangiitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Granulomatosis with Polyangiitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Granulomatosis with Polyangiitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Granulomatosis with Polyangiitis Drug Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Granulomatosis with Polyangiitis Drug Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Avacopan
  • Benralizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Sandoz International GmbH
  • GlaxoSmithKline Plc
  • The International Biotechnology Center (IBC) Generium
  • Panacea Biotec Ltd
  • Iltoo Pharma
  • Genor BioPharma Co Ltd
  • Coherus BioSciences Inc
  • ChemoCentryx Inc
  • Bristol-Myers Squibb Company
  • Bionovis SA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Granulomatosis with Polyangiitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Granulomatosis with Polyangiitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Granulomatosis with Polyangiitis Drug Market by Type
  6. 1.3.1 Avacopan
  7. 1.3.2 Benralizumab
  8. 1.3.3 Rituximab Biosimilar
  9. 1.3.4 Others
  10. 1.4 Global Granulomatosis with Polyangiitis Drug Market Size by Type
  11. 1.4.1 Global Granulomatosis with Polyangiitis Drug Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Granulomatosis with Polyangiitis Drug Industry Trends
  2. 2.2 Granulomatosis with Polyangiitis Drug Industry Drivers
  3. 2.3 Granulomatosis with Polyangiitis Drug Industry Opportunities and Challenges
  4. 2.4 Granulomatosis with Polyangiitis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Granulomatosis with Polyangiitis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Granulomatosis with Polyangiitis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Granulomatosis with Polyangiitis Drug Price (2021-2026)
  4. 3.4 Global Granulomatosis with Polyangiitis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Granulomatosis with Polyangiitis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Granulomatosis with Polyangiitis Drug Company, Product Type & Application
  7. 3.7 Global Granulomatosis with Polyangiitis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Granulomatosis with Polyangiitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Granulomatosis with Polyangiitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Granulomatosis with Polyangiitis Drug Tier 1, Tier 2, and Tier 3
4 Granulomatosis with Polyangiitis Drug Regional Status and Outlook
  1. 4.1 Global Granulomatosis with Polyangiitis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size by Region
  3. 4.2.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Granulomatosis with Polyangiitis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Granulomatosis with Polyangiitis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Granulomatosis with Polyangiitis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Granulomatosis with Polyangiitis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Granulomatosis with Polyangiitis Drug by Application
  1. 5.1 Granulomatosis with Polyangiitis Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Granulomatosis with Polyangiitis Drug Market Size by Application
  6. 5.2.1 Global Granulomatosis with Polyangiitis Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Sandoz International GmbH
  2. 6.1.1 Sandoz International GmbH Company Information
  3. 6.1.2 Sandoz International GmbH Business Overview
  4. 6.1.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product Portfolio
  6. 6.1.5 Sandoz International GmbH Recent Developments
  7. 6.2 GlaxoSmithKline Plc
  8. 6.2.1 GlaxoSmithKline Plc Company Information
  9. 6.2.2 GlaxoSmithKline Plc Business Overview
  10. 6.2.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product Portfolio
  12. 6.2.5 GlaxoSmithKline Plc Recent Developments
  13. 6.3 The International Biotechnology Center (IBC) Generium
  14. 6.3.1 The International Biotechnology Center (IBC) Generium Company Information
  15. 6.3.2 The International Biotechnology Center (IBC) Generium Business Overview
  16. 6.3.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product Portfolio
  18. 6.3.5 The International Biotechnology Center (IBC) Generium Recent Developments
  19. 6.4 Panacea Biotec Ltd
  20. 6.4.1 Panacea Biotec Ltd Company Information
  21. 6.4.2 Panacea Biotec Ltd Business Overview
  22. 6.4.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  24. 6.4.5 Panacea Biotec Ltd Recent Developments
  25. 6.5 Iltoo Pharma
  26. 6.5.1 Iltoo Pharma Company Information
  27. 6.5.2 Iltoo Pharma Business Overview
  28. 6.5.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Product Portfolio
  30. 6.5.5 Iltoo Pharma Recent Developments
  31. 6.6 Genor BioPharma Co Ltd
  32. 6.6.1 Genor BioPharma Co Ltd Company Information
  33. 6.6.2 Genor BioPharma Co Ltd Business Overview
  34. 6.6.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product Portfolio
  36. 6.6.5 Genor BioPharma Co Ltd Recent Developments
  37. 6.7 Coherus BioSciences Inc
  38. 6.7.1 Coherus BioSciences Inc Company Information
  39. 6.7.2 Coherus BioSciences Inc Business Overview
  40. 6.7.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  42. 6.7.5 Coherus BioSciences Inc Recent Developments
  43. 6.8 ChemoCentryx Inc
  44. 6.8.1 ChemoCentryx Inc Company Information
  45. 6.8.2 ChemoCentryx Inc Business Overview
  46. 6.8.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product Portfolio
  48. 6.8.5 ChemoCentryx Inc Recent Developments
  49. 6.9 Bristol-Myers Squibb Company
  50. 6.9.1 Bristol-Myers Squibb Company Company Information
  51. 6.9.2 Bristol-Myers Squibb Company Business Overview
  52. 6.9.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 6.10 Bionovis SA
  56. 6.10.1 Bionovis SA Company Information
  57. 6.10.2 Bionovis SA Business Overview
  58. 6.10.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Bionovis SA Granulomatosis with Polyangiitis Drug Product Portfolio
  60. 6.10.5 Bionovis SA Recent Developments
7 North America by Country
  1. 7.1 North America Granulomatosis with Polyangiitis Drug Sales by Country
  2. 7.1.1 North America Granulomatosis with Polyangiitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Granulomatosis with Polyangiitis Drug Market Size by Country
  6. 7.2.1 North America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Granulomatosis with Polyangiitis Drug Sales by Country
  2. 8.1.1 Europe Granulomatosis with Polyangiitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Granulomatosis with Polyangiitis Drug Market Size by Country
  6. 8.2.1 Europe Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Granulomatosis with Polyangiitis Drug Sales by Country
  2. 10.1.1 South America Granulomatosis with Polyangiitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Granulomatosis with Polyangiitis Drug Market Size by Country
  6. 10.2.1 South America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Granulomatosis with Polyangiitis Drug Value Chain Analysis
  2. 12.1.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Granulomatosis with Polyangiitis Drug Production Mode & Process
  7. 12.2 Granulomatosis with Polyangiitis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Granulomatosis with Polyangiitis Drug Distributors
  10. 12.2.3 Granulomatosis with Polyangiitis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst